Not all body fat carries equal health risk. Subcutaneous fat sits just beneath the skin and is relatively metabolically inert. Visceral fat, the fat that accumulates around and between abdominal organs, produces hormones and inflammatory signals that drive cardiovascular disease, insulin resistance, and metabolic syndrome. Two people with the same total body weight and even the same BMI can have dramatically different metabolic risk profiles depending on where their fat is stored.
What Visceral Fat Is
Visceral fat occupies the abdominal cavity surrounding the liver, pancreas, intestines, and other organs. It is distinct from the fat that makes up a visible “belly”, much of what is visible as abdominal fat is subcutaneous. True visceral fat is not visible externally and does not compress when you lie down the way subcutaneous fat does.
Visceral fat cells behave differently from subcutaneous fat cells at the cellular level. They have higher rates of lipolysis (fat breakdown) and release free fatty acids directly into the portal circulation, which flows directly to the liver. This fatty acid delivery to the liver contributes to non-alcoholic fatty liver disease, insulin resistance, and increased production of inflammatory cytokines. Visceral fat also secretes adipokines, hormonal signals including interleukin-6, tumor necrosis factor-alpha, and PAI-1, at higher rates than subcutaneous fat. These signals promote systemic inflammation and impair insulin signaling throughout the body.
How to Estimate Visceral Fat
No inexpensive consumer measurement accurately quantifies visceral fat. The reference standard is MRI or CT imaging, which can directly measure the volume of fat within the abdominal cavity. These are expensive and involve radiation (CT) or are not routinely available as standalone tests.
Waist circumference is the most practical proxy. The National Institutes of Health defines increased health risk at waist circumference above 35 inches (88 cm) in women and above 40 inches (102 cm) in men. These thresholds are imperfect, they do not account for height or frame, but provide a reasonable initial screen.
Waist-to-hip ratio adds context. Dividing waist circumference by hip circumference gives a number that reflects whether fat distribution is more abdominal (apple shape, higher visceral risk) or gluteal-femoral (pear shape, lower visceral risk). A ratio above 0.9 in men and 0.85 in women is associated with higher metabolic risk in WHO guidelines.
Bioelectrical impedance scales and DEXA scans can estimate total body fat percentage and distribution with moderate accuracy but still do not isolate visceral from subcutaneous fat precisely.
What Drives Visceral Fat Accumulation
Sex hormones: Men tend to store more visceral fat than women at equivalent body fat percentages. After menopause, as estrogen falls, women’s fat distribution shifts toward more visceral accumulation. Testosterone deficiency in men is consistently associated with higher visceral fat, as covered in 9 Signs of Low Testosterone That Men Frequently Dismiss.
Cortisol: Chronic stress elevates cortisol, which specifically promotes visceral fat deposition through cortisol receptor density in abdominal fat cells. This is why prolonged stress exposure disproportionately adds abdominal fat rather than distributing fat more evenly.
Sleep insufficiency: Poor sleep increases cortisol, ghrelin, and insulin resistance, all of which favor visceral fat accumulation. Short sleep duration is independently associated with greater visceral fat in prospective studies.
Diet composition: Excessive refined carbohydrate and fructose intake is more strongly associated with visceral fat accumulation than equivalent caloric intake from other macronutrients. High-fructose diets drive de novo lipogenesis in the liver, which preferentially deposits as visceral fat.
Physical inactivity: Visceral fat is more metabolically responsive to exercise than subcutaneous fat. Aerobic exercise reduces visceral fat preferentially, even without significant changes in total body weight.
How GLP-1 Medications Affect Visceral Fat
GLP-1 receptor agonists including semaglutide and tirzepatide produce preferential reduction in visceral fat relative to subcutaneous fat during weight loss. MRI studies in GLP-1 trials confirm this: participants lose a larger proportion of their visceral fat than their subcutaneous fat. This is clinically relevant because visceral fat reduction drives most of the metabolic benefit, improvements in blood pressure, triglycerides, glucose, and inflammatory markers correlate more closely with visceral fat loss than with total weight lost.
This preferential visceral fat reduction is one reason GLP-1 medications often produce metabolic improvements, reduced blood pressure, improved lipids, lower fasting glucose, that appear disproportionate to the amount of total weight lost.
For context on how weight management medications work, see What Is Semaglutide and How Does It Work for Weight Loss? and What Is Tirzepatide and How Does It Work?
